Incidence, duration, and severity of neutropenia in adults with B-cell acute lymphoblastic leukemia receiving blinatumomab consolidation
Evan C. Chen(Dana-Farber Cancer Institute), Marlise R. Luskin(Dana-Farber Cancer Institute), Yael Flamand(Dana-Farber Cancer Institute), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Emily Tiao(Dana-Farber Cancer Institute)
Cited by 2
Related Papers
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464